{"id":"NCT00694304","sponsor":"H. Lundbeck A/S","briefTitle":"Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults","officialTitle":"A Long-term, Open-label, Flexible-dose, Extension Study Evaluating the Safety and Tolerability of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2010-03","completion":"2010-04","firstPosted":"2008-06-10","resultsPosted":"2014-04-01","lastUpdate":"2014-04-01"},"enrollment":535,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Vortioxetine (Lu AA21004)","otherNames":["Brintellix"]}],"arms":[{"label":"Vortioxetine","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 8-week acute treatment.","primaryOutcome":{"measure":"Number of Patients With Adverse Events (AEs)","timeFrame":"Baseline to end of the 4-week safety follow-up period","effectByArm":[{"arm":"Vortioxetine 2.5, 5, or 10 mg/Day","deltaMin":391,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22978748"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":535},"commonTop":["Nausea","Headache","Nasopharyngitis","Insomnia","Dizziness"]}}